View source for 20240016859. MICROENCAPSULATED AND CHROMOSOME INTEGRATED COMPOSITIONS FOR L-DOPA MICROBIOME THERAPY simplified abstract (Iowa State University Research Foundation, Inc.)

=MICROENCAPSULATED AND CHROMOSOME INTEGRATED COMPOSITIONS FOR L-DOPA MICROBIOME THERAPY=


==Organization Name==

[[:Category:Iowa State University Research Foundation, Inc.|Iowa State University Research Foundation, Inc.]]


[[Category:Iowa State University Research Foundation, Inc.]]

==Inventor(s)==

[[:Category:Anumantha G. Kanthasamy of Ames IA (US)|Anumantha G. Kanthasamy of Ames IA (US)]][[Category:Anumantha G. Kanthasamy of Ames IA (US)]]

[[:Category:Gregory Phillips of Ames IA (US)|Gregory Phillips of Ames IA (US)]][[Category:Gregory Phillips of Ames IA (US)]]

[[:Category:Ahmed Abdalla of Ames IA (US)|Ahmed Abdalla of Ames IA (US)]][[Category:Ahmed Abdalla of Ames IA (US)]]

[[:Category:Nicholas John Backes of Ames IA (US)|Nicholas John Backes of Ames IA (US)]][[Category:Nicholas John Backes of Ames IA (US)]]

[[:Category:Piyush Padhi of Ames IA (US)|Piyush Padhi of Ames IA (US)]][[Category:Piyush Padhi of Ames IA (US)]]

==MICROENCAPSULATED AND CHROMOSOME INTEGRATED COMPOSITIONS FOR L-DOPA MICROBIOME THERAPY - A simplified explanation of the abstract==


This abstract first appeared for US patent application 20240016859 titled 'MICROENCAPSULATED AND CHROMOSOME INTEGRATED COMPOSITIONS FOR L-DOPA MICROBIOME THERAPY

==Simplified Explanation==

The present invention is about methods and compositions for treating Parkinson's disease, Alzheimer's disease, depression, anxiety, and memory deficits. It involves the use of recombinant microorganisms, specifically gut-colonizing probiotics, that have been modified to produce l-dopa. The invention also includes microcapsules and lyophilized formulations containing these modified microorganisms.

* The invention focuses on the treatment of neurological disorders such as Parkinson's disease, Alzheimer's disease, depression, anxiety, and memory deficits.
* It involves the use of recombinant microorganisms, particularly gut-colonizing probiotics, that have been genetically modified to produce l-dopa.
* The invention also includes microcapsules and lyophilized formulations that contain these modified microorganisms.
* The production of l-dopa by the modified microorganisms offers a potential therapeutic approach for these neurological disorders.
* The microcapsules and lyophilized formulations provide convenient and stable delivery systems for the modified microorganisms.

== Potential Applications ==
* Treatment of Parkinson's disease
* Treatment of Alzheimer's disease
* Treatment of depression
* Treatment of anxiety
* Treatment of memory deficits

== Problems Solved ==
* Lack of effective treatments for Parkinson's disease, Alzheimer's disease, depression, anxiety, and memory deficits
* Limited availability of l-dopa, a key therapeutic agent for Parkinson's disease
* Challenges in delivering therapeutic agents to the gut for neurological disorders

== Benefits ==
* Novel therapeutic approach using genetically modified microorganisms
* Potential for targeted delivery to the gut, where the modified microorganisms can colonize and produce l-dopa
* Microcapsules and lyophilized formulations provide convenient and stable delivery systems for the modified microorganisms


==Original Abstract Submitted==

the present invention generally provides methods and compositions for the treatment of parkinson's disease, alzheimer's disease, depression, anxiety, and memory deficits. the invention relates to recombinant microorganisms, particularly gut-colonizing probiotics, modified to produce l-dopa as well as microcapsules and lyophilized formulations comprising the same.



[[Category:C12N1/20]]
[[Category:A61P25/28]]